

Rezdiffra - Non-PDL
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:		Prescriber Name:	
HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a request for renewal? If YES, go to question 2. If NO, go to question 4

☐ Yes

☐ No

Q2. Is the patient prescribed a dose and duration of therapy consistent with the FDA approved package labeling?

☐ Yes

☐ No

Q3. Will the patient follow a reduced-calorie diet and increased physical activity plan?

☐ Yes

☐ No

Q4. For a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), does the patient have any of the following?

☐ Hepatic decompensation or a Model for End-Stage Liver Disease (MELD) score of more than 12 points at screening

☐ Significant alcohol consumption (> 20 grams of alcohol per day for women and > 30 grams for men)

☐ An aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level of more than 5 times the upper limit of the normal range at screening

☐ An estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73 m2

Rezdiffra - Non-PDL
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:

Prescriber Name:

- ☐ Presence or history of hepatocellular carcinoma (HCC)
- ☐ History of acute pancreatitis
- ☐ Chronic liver diseases other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g., primary biliary cholangitis, primary sclerosing cholangitis, Hepatitis B positive, Active Hepatitis C, etc.)

Q5. For noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), has the patient had positive clinical effects as evidenced by any of the following:

- ☐ Optimal control of comorbid metabolic conditions with pertinent labs attached
- ☐ Weight loss (including recent BMI and weight)
- ☐ No worsening of MASH as evidenced by improvement in liver enzyme levels and/or non-invasive fibrosis markers if available

Q6. Does the patient continue to take optimized pharmacotherapy for established hypertension, dyslipidemia, or diabetes, if applicable?

- ☐ Yes ☐ No

Q7. Is there documentation of positive clinical response and tolerability to requested medication?

- ☐ Yes ☐ No

Q8. Is the patient 18 years of age or older?

- ☐ Yes ☐ No

Q9. Is the medication prescribed by or in consultation with a hepatologist or gastroenterologist?

- ☐ Yes ☐ No

Q10. Does the patient have any of the following? A. Stage F4 liver fibrosis (cirrhosis); B. Significant alcohol consumption (2 alcoholic drinks per day) for a duration of more than 3 months in the last year; C. Diagnosis of hepatocellular carcinoma (HCC); D. Chronic liver diseases (e.g., primary biliary cholangitis, primary sclerosing cholangitis, Hepatitis B positive, Active Hepatitis C, etc.)

- ☐ Yes ☐ No

Rezdiffra - Non-PDL**Phone: 215-991-4300****Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:

Prescriber Name:

Q11. Is there a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) confirmed by liver biopsy or imaging confirming steatosis with results attached? (Imaging studies can include ultrasound, Fibroscan CAP, or MRI-PDFF).

☐ Yes☐ No

Q12. For a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), does the patient have any of the following?

- ☐ Hepatic decompensation or a Model for End-Stage Liver Disease (MELD) score of more than 12 points at screening
- ☐ Significant alcohol consumption (> 20 grams of alcohol per day for women and > 30 grams for men)
- ☐ An aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level of more than 5 times the upper limit of the normal range at screening
- ☐ An estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73 m²
- ☐ Presence or history of hepatocellular carcinoma (HCC)
- ☐ History of acute pancreatitis
- ☐ Chronic liver diseases other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g., primary biliary cholangitis, primary sclerosing cholangitis, Hepatitis B positive, Active Hepatitis C, etc.)

Q13. Does the patient have moderate to advanced liver fibrosis (stages F2 or F3) confirmed by liver biopsy performed within the last 6 months?

☐ Yes☐ No

Q14. Does the patient have moderate to advanced liver fibrosis(stage F2 or F3)confirmed by ONE of the following tests performed within the last 6 months: i. Liver biopsy; ii.One of the following non-invasive tests: a. Transient elastography (e.g., Fibroscan) ; b. Shear wave elastography (SWE) ; c. Magnetic resonance elastography (MRE)

☐ Yes☐ No

Q15. Is the patient prescribed a dose and duration of therapy consistent with the FDA approved package labeling?

☐ Yes☐ No

Rezdiffra - Non-PDL**Phone: 215-991-4300****Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:

Prescriber Name:

Q16. Will the patient follow a reduced-calorie diet and increased physical activity plan?☐ Yes☐ No**Q17. Is there documentation of counseling the patient on dietary and lifestyle modifications?**☐ Yes☐ No**Q18. Additional Information:**☐ Yes☐ No_____
Prescriber Signature_____
Date

v2026